Kye Y. Kim

What Is the Evidence to Support the Use of Therapeutic Gardens for the Elderly

Horticulture therapy employs plants and gardening activities in therapeutic and rehabilitation activities and could be utilized to improve the quality of life of the worldwide aging population, possibly reducing costs for long-term, assisted living and dementia unit residents. Preliminary studies have reported the benefits of horticultural therapy and garden settings in reduction of pain, improvement in attention, lessening of stress, modulation of agitation, lowering of as needed medications, antipsychotics and reduction of falls. This is especially relevant for both the United States and the Republic of Korea since aging is occurring at an unprecedented rate, with Korea experiencing some of the worlds greatest increases in elderly populations. In support of the role of nature as a therapeutic modality in geriatrics, most of the existing studies of garden settings have utilized views of nature or indoor plants with sparse studies employing therapeutic gardens and rehabilitation greenhouses. With few controlled clinical trials demonstrating the positive or negative effects of the use of garden settings for the rehabilitation of the aging populations, a more vigorous quantitative analysis of the benefits is long overdue. This literature review presents the data supporting future studies of the effects of natural settings for the long term care and rehabilitation of the elderly having the medical and mental health problems frequently occurring with aging.

Longitudinal analysis of differential effects on agitation of a therapeutic wander garden for dementia patients based on ambulation ability

A growth model within the framework of hierarchical linear modeling was used to assess the impact of visiting a wander garden on monthly agitation levels of a group of elderly veterans diagnosed with dementia, with attention to their ambulatory ability. A sample of 34 veterans residing in a locked ward in a dementia unit was observed for a baseline period and for twelve months after a wander garden was opened in their facility. Findings suggest that visiting the wander garden helped lower agitation levels in the dementia patients and that there was a differential effect based on the patient’s ability to walk unassisted.

Anti-Amyloid Treatments in Alzheimers Disease

Alzheimers disease is one of the most challenging threats to the healthcare system in society. One of the main characteristic of Alzheimers disease (AD) pathology is formation of amyloid plaques from accumulation of amyloid beta peptide. The therapeutic agents that are currently available for AD including acetylcholinesterase inhibitors (AchEIs) and the N-methyl-D-aspartate (NMDA) antagonist are focused on improving the symptoms and do not revert the progression of the disease. This limitation coupled with the burgeoning increase in the prevalence of AD and resultant impact on healthcare economics calls for more substantial treatments for AD. According to the leading amyloid hypothesis, cleavage of amyloid precursor protein to release amyloid beta peptide is the critical event in pathogenesis of Alzheimers disease. Recently treatment strategies have been focused on modifying the formation, clearance and accumulation of neurotoxic amyloid beta peptide. This article reviews different therapeutic approaches that have been investigated to target amyloid beta ranging from secretase modulators, antiaggregation agents to amyloid immunotherapy. Authors review the different novel drugs which are in clinical trials.

Case Reports of Neuroleptic Malignant Syndrome in Context of Quetiapine Use

A retrospective analysis was followed on 20 case reports covering the possible correlation between the atypical antipsychotic, quetiapine, and neuroleptic malignant syndrome (NMS), determined by the study of 7 different NMS criteria guidelines. A great majority (19) of the case studies did not meet the requirements of all 7 guidelines, frequently due to unreported information. Nor was quetiapine proven to be the sole cause of the possible NMS in the two age groups investigated. Only one case was found to have no other medication or medical conditions confounding the relationship of quetiapine and NMS symptoms, and that case was in the context of a significant quetiapine overdose. The other 19 cases demonstrated the difficulty of identifying the cause of NMS when polypharmacy and other medical conditions are involved. The authors note the need for caution in deciding both the presence of NMS and the causal factors of the symptoms.

Relationship of Physical and Functional Independence and Perceived Quality of Life of Veteran Patients With Alzheimer Disease

Alzheimer disease not only affects the cognitive function but also impacts one’s abilities to perform daily tasks. This study evaluated for correlation between the quality of life of patients with Alzheimer disease (QoL-AD) and the level of independence and to evaluate the statistical difference between patients’ quality of life and proxy perception of quality of life by utilizing the Katz activities of daily living and QoL-AD on patients and QoL-AD on caregivers. There was a small positive correlation (r = .13) between the levels of physical and functional independence and the perceived QoL. Also, patient consistently had higher QoL-AD than their caregiver counterparts. These findings provide some insight into our need to acknowledge factors that may influence QoL and illustrate the importance of monitoring for executive dysfunction and the safety risk.

Risperidone for post-traumatic combat nightmares: a report of four cases.

OBJECTIVE To report the response to low-dose risperidone in individuals with combat-related post-traumatic stress disorder (PTSD) combat nightmares. DESIGN Case series. SETTING Veterans Affairs Medical Center Mental Health Clinic and collaborative VA-U.S. Army Fort Bragg Warrior Transition Telepsychiatry Clinic. PRACTICE DESCRIPTION Veterans at the VA; soldiers that have severe medical and mental health problems in the Warrior Transition Telepsychiatry Clinic. MAIN OUTCOME MEASURE(S) No response: no change in frequency and/or severity of nightmares; partial response: decrease in frequency and/or severity of nightmares; full response: total cessation of recall of nightmares. RESULTS The four individuals included one active duty soldier and three veterans, ranging from 40 to 76 years of age. All served in the infantry, each in a different combat theater. Two participants had a reduction in the frequency and severity of nightmares at risperidone 1 mg at night. One veteran with blood alcohol levels greater than 300 mg/mL had a partial response with risperidone 3 mg at night. Without active substance abuse, the four individuals had a total cessation of nightmares the first night at a risperidone dose of 2 mg at night. The total cessation of nightmares with risperidone continued despite changes in concurrent antidepressants, anxiolytics, and hypnotics. No medication side effects were reported. CONCLUSION The use of low-dose risperidone (1-3 mg) at night can reduce the severity and frequency or stop the recall of PTSD combat nightmares in some veterans and active duty soldiers. Risperidone may be an effective medication for combat nightmares of PTSD and merits additional exploration.

Grief Experiences of 3 Caregiving Wives of Veterans With Dementia

Three wives share their experiences of caregiving for husbands with dementia. The 3 husbands, aged 51, 71, and 84, developed dementia following years of devoted military service. To present lived experiences of caregiving wives’, meanings attributed to caregiving are investigated, variations in caregiving and grieving experiences are explored, and therapeutic implications are offered. Through case study approach and with issues of caregiver grief considered, we introduce life course and ambiguous loss theoretical perspectives. Emergent qualitative themes and quantitative inventory ratings indicate significant differences in caregiver grief response depend on care-recipient age. Practice implications and directions for future care recipient, age-related research are presented.

Providing Quality Palliative Care in End-Stage Alzheimer Disease

Providing quality palliative care is a daunting task profoundly impacted by diminished patient capacity at the end of life. Alzheimer disease (AD) is a disorder that erases our memories and is projected to increase dramatically for decades to come. By the time the patients with AD reach the end stage of the disease, the ability of patients to provide pertinent subjective complaints of pain and discomfort would have vanished. Historical perspectives of palliative care, exploration of the AD process, ethical issues, and crucial clinical considerations are provided to improve the understanding of disease progression and quality of care for patients with end-stage AD.

A case of intention tremor induced by the combination of aripiprazole and lamotrigine.

To the Editor: In patients with chronic disabling psychiatric conditions in whom many therapeutic interventions have been implemented, augmentation and combination therapies are commonly used to improve the outcome. The number of visits during which a psychotropic medication was prescribed increased from 32.73 million to 45.64 million in less than 10 years in office-based physician practices in the United States.1 Here, we report a case of intention tremor induced by a combination of aripiprazole and lamotrigine. Case report. Ms A was a 60-year-old white woman with a 6-year history of DSM-IV major depressive disorder and generalized anxiety disorder and no history of psychiatric hospitalizations. Her past medical and surgical history was significant for type 2 diabetes mellitus, above-knee amputation, hysterectomy, and arthritis. Her family history was negative for psychiatric disorders. She denied smoking, drinking alcohol, or using illegal drugs. Multiple medications were tried before Ms A became stable on treatment with lamotrigine 300 mg/d for several years. Although the patient was stable, there was room for improvement in her symptoms, and in February 2011, aripiprazole 5 mg/d was added as an augmenting agent. The patients symptoms improved, and she became socially active, volunteering at the local hospital and spending time with her friends. However, 2 months after starting aripiprazole treatment, the patient developed a disabling intention tremor in her hands, head, and jaw. Lamotrigine was tapered off slowly with no deterioration of her mood and complete resolution of her tremor. Moreover, she reported maintaining an active social life at 3-, 6-, and 12-month follow-up. Our patient was prescribed both lamotrigine and aripiprazole for major depression, and she had a therapeutic response, but we noted an interesting adverse effect that can be attributed only to the concomitant prescription of these medications. Aripiprazole, like other atypical antipsychotics, displays antagonistic action at serotonin-2A (5-HT2A) receptors. However, it differs from other antipsychotics in that it is a partial agonist at dopamine-2 receptors and 5-HT1A receptors.2 Both cytochrome P450 (CYP) 3A4 and the polymorphic enzyme CYP2D6 are involved in the metabolism of aripiprazole to its main metabolite dehydroaripiprazole.3 On the other hand, lamotrigine is metabolized predominantly by glucuronic acid conjugation, mainly by UDP-glucuronosyltransferase 1A4 with the inactive 2-N-glucuronide conjugate as the major metabolite.4 Literature suggests that lamotrigine increases the concentration to dose ratios of aripiprazole by 51%.5 According to the Naranjo Adverse Drug Reactions Probability Scale, the intention tremor reaction reported in this case can be classified as a “probable” association between the combination of aripiprazole and lamotrigine and the side effect.6 The onset of the clinical adverse effect is consistent with the administration of the drugs together, and the effect was not present when either drug alone was given to the patient. To our knowledge, this is the first report of a clinical interaction of aripiprazole and lamotrigine that resulted in intention tremor. We anticipate that many more such cases will surface as combination treatment becomes a norm in the treatment of psychiatric illnesses. Clinicians should be vigilant against this problem and should be ready to adjust treatment with discontinuation of either medication if faced with such an adverse effect in their patients.